Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on April 7, 2020, regarding an event that occurred on April 1, 2020. The Company is incorporated in Nevada and its common stock and warrants trade on The Nasdaq Capital Market under the symbols "CTXR" and "CTXRW," respectively.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
On April 1, 2020, the Company received written notice from The Nasdaq Stock Market indicating noncompliance with Rule 5550(a)(2) of the Nasdaq Listing Rules. The noncompliance stems from the closing bid price of the Company's common stock falling below $1.00 per share for 30 consecutive business days.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial compliance period of 180 calendar days, ending on September 28, 2020, to regain compliance.
- Regaining Compliance: To cure the deficiency, the closing bid price must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to September 28, 2020.
- Future Options: If the Company fails to regain compliance by the initial deadline, it may be eligible for an additional 180-day grace period, provided it meets all other initial listing standards (excluding the bid price) and notifies Nasdaq of its intent to cure.
- Delisting Risk: If the Company cannot cure the deficiency or is ineligible for an additional period, Nasdaq will issue a notice of delisting. The Company retains the right to appeal such a determination, during which the stock would remain listed.
- Management Action: Management intends to consider all available alternatives to regain compliance and maintain the listing.
Investor Verification Checklist
- Verify the current closing bid price of CTXR to assess the likelihood of meeting the $1.00 threshold within the 180-day window.
- Monitor subsequent filings for any announcements regarding reverse stock splits or other corporate actions intended to increase the share price.
- Check for any updates on the Company's ability to meet other Nasdaq listing standards (e.g., market value of publicly held shares) in case a second compliance period is required.
- Review the Company's cash position in other filings (10-K/10-Q) to ensure sufficient liquidity to sustain operations while addressing the listing deficiency.